IPP Bureau
GenSci launches global innovation hub in Shanghai
By IPP Bureau - December 26, 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
By IPP Bureau - December 26, 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
By IPP Bureau - December 26, 2023
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
By IPP Bureau - December 26, 2023
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
By IPP Bureau - December 26, 2023
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas completes acquisition of Propella Therapeutics
By IPP Bureau - December 26, 2023
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Eugia's East Windsor facility gets 10 observations from USFDA
By IPP Bureau - December 25, 2023
The plant is yet to start commercial operations
Stelis Biopharma updates on receipt of consideration from Syngene
By IPP Bureau - December 25, 2023
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Ind-Swift Laboratories receives award from World HRD Congress
By IPP Bureau - December 25, 2023
World HRD Congress is a well-known international body of Management Studies
Lyndra Therapeutics raises US$101 million in Series E funding
By IPP Bureau - December 25, 2023
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
By IPP Bureau - December 24, 2023
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan
By IPP Bureau - December 23, 2023
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
By IPP Bureau - December 23, 2023
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi
By IPP Bureau - December 23, 2023
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer
By IPP Bureau - December 23, 2023
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
